×
About 22,366 results

ALLMedicine™ Hypercholesterolemia Center

Research & Reviews  8,607 results

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hyperchole...
https://doi.org/10.1016/j.jacc.2020.12.058
Journal of the American College of Cardiology; Wright RS, Ray KK et. al.

Mar 5th, 2021 - Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atheroge...

A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterole...
https://doi.org/10.5551/jat.58909
Journal of Atherosclerosis and Thrombosis; Nishikawa R, Furuhashi M et. al.

Mar 1st, 2021 - A 56-year-old postmenopausal woman with out-of-hospital cardiac arrest caused by acute myocardial infraction was successfully resuscitated by intensive treatments and recovered without any neurological disability. She was diagnosed as having famil...

Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic acti...
https://doi.org/10.1016/j.ebiom.2021.103250
EBioMedicine Xu M, Lei G et. al.

Mar 1st, 2021 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL cholesterol (LDL-C) levels by facilitating the degradation of the LDL receptor (LDLR) and is an attractive therapeutic target for hypercholesterolemia intervention. Herein, ...

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913462
Orphanet Journal of Rare Diseases; Víšek J, Bláha M et. al.

Feb 28th, 2021 - Lipoprotein apheresis (LA) is considered as an add-on therapy for patients with familial hypercholesterolemia (FH). We aimed to analyze the data collected in the last 15 years from FH patients treated with LA, to elucidate the benefit of this proc...

Beneficial Metabolic Effects of TREM2 in Obesity are Uncoupled from its Expression on M...
https://doi.org/10.2337/db20-0572
Diabetes Sharif O, Brunner JS et. al.

Feb 25th, 2021 - Obesity-induced white adipose tissue (WAT) hypertrophy is associated with elevated adipose tissue macrophage (ATM) content. Overexpression of the triggering receptor expressed on myeloid cells 2 (TREM2) reportedly increases adiposity, worsening he...

see more →

Guidelines  27 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Statin Use and the Site-Specific Risk of Colorectal Cancer in Individuals with Hypercholesterolemia from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS)
https://www.sciencedirect.com/science/article/pii/S0939475319301164?via%3Dihub
Nutrition, Metabolism and Cardiovascular Diseases; Lee,J.,et al

Apr 12th, 2019 - Background and Aims We investigated the association between statin use and site-specific risk of colorectal cancer in individuals with hypercholesterolemia. Methods and Results This study is based on the National Health Insurance Service-National...

Lipid levels and the risk of hemorrhagic stroke among women
https://n.neurology.org/content/early/2019/04/10/WNL.0000000000007454
Rist,P.,et al

Apr 9th, 2019 - Objective To examine the association between lipid levels and hemorrhagic stroke risk among women. Methods We performed a prospective cohort study among 27,937 women enrolled in the Women's Health Study with measured total cholesterol, low-densit...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of ...
http://www.onlinejacc.org/content/early/2018/11/02/j.jacc.2018.11.003
Grundy, S.,et al

Nov 9th, 2018 - The recommendations listed in the present guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLIN.

see more →

Drugs  1,837 results see all →

Clinicaltrials.gov  11,095 results

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hyperchole...
https://doi.org/10.1016/j.jacc.2020.12.058
Journal of the American College of Cardiology; Wright RS, Ray KK et. al.

Mar 5th, 2021 - Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atheroge...

Fenofibrate - fenofibrate tablet, film coated-Sun Pharmaceutical Industries, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c5062d-e8ad-44e7-a709-af0092f73d52

Mar 3rd, 2021 - Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: •To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed ...

Atorvastatin calcium - atorvastatin calcium tablet, film coated-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09cb8375-075c-47e8-a4eb-8ac667ed849e

Mar 2nd, 2021 - Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an...

Rosuvastatin calcium - rosuvastatin calcium tablet, coated-Major Pharmaceuticals
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2cda59-2bdc-49de-98cd-53ac6b0decdb

Mar 2nd, 2021 - Rosuvastatin tablets are an HMG Co-A reductase inhibitor indicated for: • adult patients with hypertriglyceridemia as an adjunct to diet ( 1.3) •  adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to ...

Fenofibrate - fenofibrate capsule-Glenmark Pharmaceuticals Inc., USA
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7204052-02cf-4b38-835b-d8754c74b2cd

Mar 2nd, 2021 - Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering...

see more →

News  795 results

FDA Approves Orphan Drug Evinacumab-dgnb for Homozygous FH
https://www.medscape.com/viewarticle/945719

Feb 10th, 2021 - The US Food and Drug Administration has approved the fully human monoclonal antibody evinacumab-dgnb (Evkeeza, Regeneron Pharmaceuticals) for use on top of other cholesterol-modifying meds in patients aged 12 and older with homozygous familial hyp...

Evinacumab, Novel Lipid-Lowerer, Extends Promise in Phase 2 Results
https://www.medscape.com/viewarticle/941043

Nov 15th, 2020 - Treatment with evinacumab, an investigational lipid-lowering drug with a novel mechanism of action, safely led to roughly a halving of LDL cholesterol levels in patients with treatment-refractory hypercholesterolemia in a multicenter, phase 2 stud...

Women With Heterozygous FH Less Likely to Receive Treatment
https://www.staging.medscape.com/viewarticle/939392

Oct 18th, 2020 - There are gender differences among patients with heterozygous familial hypercholesterolemia (HeFH) in terms of when the disease is diagnosed, how it is treated, and the levels of low-density lipoprotein (LDL) cholesterol attained, suggest data fro...

Women With Heterozygous FH Less Likely to Receive Treatment
https://www.medscape.com/viewarticle/939392

Oct 18th, 2020 - There are gender differences among patients with heterozygous familial hypercholesterolemia (HeFH) in terms of when the disease is diagnosed, how it is treated, and the levels of low-density lipoprotein (LDL) cholesterol attained, suggest data fro...

Inclisiran Effectively Lowers LDL Across High-risk Settings
https://www.staging.medscape.com/viewarticle/939172

Oct 14th, 2020 - Inclisiran (The Medicines Company) sustainably reduces low-density-lipoprotein (LDL) cholesterol levels across genotypes in heterozygous familial hypercholesterolemia (HeFH) and in the primary prevention setting in high-risk patients, suggest the ...

see more →

Patient Education  5 results see all →